APO Research
Talk to an analyst

APO RESEARCH · REPORT

Hereditary Angioedema Drug

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Hereditary Angioedema Drug Industry Growth and Trends Forecast to 2032

20 December 202598 pages

Choose your research edition.

Industry ResearchHereditary Angioedema Drug Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Hereditary Angioedema Drug Industry Growth and Trends Forecast to 203298 pages · $3,450 USDMarket StructureGlobal Hereditary Angioedema Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032187 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Hereditary Angioedema Drug Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Hereditary Angioedema Drug Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Hereditary Angioedema Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Hereditary Angioedema Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Hereditary Angioedema Drug is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Hereditary Angioedema Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Hereditary Angioedema Drug include Takeda, Pharming Group NV, Ionis Pharmaceuticals, Inc., IBio Inc., CSL Limited and BioCryst Pharmaceuticals, Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Hereditary Angioedema Drug market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Hereditary Angioedema Drug market size, estimates, and forecasts are presented in terms of sales volume (W Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Hereditary Angioedema Drug market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Hereditary Angioedema Drug.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Hereditary Angioedema Drug market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Hereditary Angioedema Drug Market by Company

Takeda

Pharming Group NV

Ionis Pharmaceuticals, Inc.

IBio Inc.

CSL Limited

BioCryst Pharmaceuticals, Inc.

Hereditary Angioedema Drug Segment by Type

C1 Esterase Inhibitor

Kallikrein Inhibitor

Selective Bradykinin B2 Receptor Antagonist

Hereditary Angioedema Drug Segment by Application

Hospital Pharmacies

Online Pharmacies

Retail Pharmacies

Hereditary Angioedema Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hereditary Angioedema Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Hereditary Angioedema Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hereditary Angioedema Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Hereditary Angioedema Drug manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Hereditary Angioedema Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of C1 Esterase Inhibitor Table 2. Major Company of Kallikrein Inhibitor Table 3. Major Company of Selective Bradykinin B2 Receptor Antagonist Table 4. Global Hereditary Angioedema Drug Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Hereditary Angioedema Drug Sales by Type (2021-2026) & (W Units) Table 6. Global Hereditary Angioedema Drug Sales Market Share in Volume by Type (2021-2026) Table 7. Global Hereditary Angioedema Drug Sales by Type (2021-2026) & (US$ Million) Table 8. Global Hereditary Angioedema Drug Sales Market Share in Value by Type (2021-2026) Table 9. Global Hereditary Angioedema Drug Price by Type (2021-2026) & (US$/Unit) Table 10. Global Hereditary Angioedema Drug Sales by Type (2027-2032) & (W Units) Table 11. Global Hereditary Angioedema Drug Sales Market Share in Volume by Type (2027-2032) Table 12. Global Hereditary Angioedema Drug Sales by Type (2027-2032) & (US$ Million) Table 13. Global Hereditary Angioedema Drug Sales Market Share in Value by Type (2027-2032) Table 14. Global Hereditary Angioedema Drug Price by Type (2027-2032) & (US$/Unit) Table 15. North America Hereditary Angioedema Drug Sales by Type (2021-2026) & (W Units) Table 16. North America Hereditary Angioedema Drug Sales by Type (2021-2026) & (US$ Million) Table 17. Europe Hereditary Angioedema Drug Sales by Type (2021-2026) & (W Units) Table 18. Europe Hereditary Angioedema Drug Sales by Type (2021-2026) & (US$ Million) Table 19. Asia-Pacific Hereditary Angioedema Drug Sales by Type (2021-2026) & (W Units) Table 20. Asia-Pacific Hereditary Angioedema Drug Sales by Type (2021-2026) & (US$ Million) Table 21. Latin America Hereditary Angioedema Drug Sales by Type (2021-2026) & (W Units) Table 22. Latin America Hereditary Angioedema Drug Sales by Type (2021-2026) & (US$ Million) Table 23. Middle East and Africa Hereditary Angioedema Drug Sales by Type (2021-2026) & (W Units) Table 24. Middle East and Africa Hereditary Angioedema Drug Sales by Type (2021-2026) & (US$ Million) Table 25. Hereditary Angioedema Drug Industry Trends Table 26. Hereditary Angioedema Drug Industry Drivers Table 27. Hereditary Angioedema Drug Industry Opportunities and Challenges Table 28. Hereditary Angioedema Drug Industry Restraints Table 29. Global Hereditary Angioedema Drug Sales Revenue by Company (US$ Million) & (2021-2026) Table 30. Global Hereditary Angioedema Drug Revenue Market Share by Company (2021-2026) Table 31. Global Hereditary Angioedema Drug Sales by Company (2021-2026) & (W Units) Table 32. Global Hereditary Angioedema Drug Sales Share by Company (2021-2026) Table 33. Global Hereditary Angioedema Drug Market Price by Company (2021-2026) & (US$/Unit) Table 34. Global Hereditary Angioedema Drug Industry Company Ranking, 2024 VS 2025 VS 2026 Table 35. Global Hereditary Angioedema Drug Major Company Production Sites and Headquarters Table 36. Global Hereditary Angioedema Drug Company, Product Type & Application Table 37. Global Hereditary Angioedema Drug Company Establishment Date Table 38. Global Company Market Concentration Ratio (CR5 and HHI) Table 39. Global Hereditary Angioedema Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 40. Global Hereditary Angioedema Drug Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 41. Global Hereditary Angioedema Drug Sales by Region (2021-2026) & (W Units) Table 42. Global Hereditary Angioedema Drug Sales Market Share in Volume by Region (2021-2026) Table 43. Global Hereditary Angioedema Drug Sales by Region (2021-2026) & (US$ Million) Table 44. Global Hereditary Angioedema Drug Sales Market Share in Value by Region (2021-2026) Table 45. Global Hereditary Angioedema Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Global Hereditary Angioedema Drug Sales by Region (2027-2032) & (W Units) Table 47. Global Hereditary Angioedema Drug Sales Market Share in Volume by Region (2027-2032) Table 48. Global Hereditary Angioedema Drug Sales by Region (2027-2032) & (US$ Million) Table 49. Global Hereditary Angioedema Drug Sales Market Share in Value by Region (2027-2032) Table 50. Global Hereditary Angioedema Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 51. Global Hereditary Angioedema Drug Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 52. Global Hereditary Angioedema Drug Sales by Application (2021-2026) & (W Units) Table 53. Global Hereditary Angioedema Drug Sales Market Share in Volume by Application (2021-2026) Table 54. Global Hereditary Angioedema Drug Sales by Application (2021-2026) & (US$ Million) Table 55. Global Hereditary Angioedema Drug Sales Market Share in Value by Application (2021-2026) Table 56. Global Hereditary Angioedema Drug Price by Application (2021-2026) & (US$/Unit) Table 57. Global Hereditary Angioedema Drug Sales by Application (2027-2032) & (W Units) Table 58. Global Hereditary Angioedema Drug Sales Market Share in Volume by Application (2027-2032) Table 59. Global Hereditary Angioedema Drug Sales by Application (2027-2032) & (US$ Million) Table 60. Global Hereditary Angioedema Drug Sales Market Share in Value by Application (2027-2032) Table 61. Global Hereditary Angioedema Drug Price by Application (2027-2032) & (US$/Unit) Table 62. North America Hereditary Angioedema Drug Sales by Application (2021-2026) & (W Units) Table 63. North America Hereditary Angioedema Drug Sales by Application (2021-2026) & (US$ Million) Table 64. Europe Hereditary Angioedema Drug Sales by Application (2021-2026) & (W Units) Table 65. Europe Hereditary Angioedema Drug Sales by Application (2021-2026) & (US$ Million) Table 66. Asia-Pacific Hereditary Angioedema Drug Sales by Application (2021-2026) & (W Units) Table 67. Asia-Pacific Hereditary Angioedema Drug Sales by Application (2021-2026) & (US$ Million) Table 68. Latin America Hereditary Angioedema Drug Sales by Application (2021-2026) & (W Units) Table 69. Latin America Hereditary Angioedema Drug Sales by Application (2021-2026) & (US$ Million) Table 70. Middle East and Africa Hereditary Angioedema Drug Sales by Application (2021-2026) & (W Units) Table 71. Middle East and Africa Hereditary Angioedema Drug Sales by Application (2021-2026) & (US$ Million) Table 72. Takeda Company Information Table 73. Takeda Business Overview Table 74. Takeda Hereditary Angioedema Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. Takeda Hereditary Angioedema Drug Product Portfolio Table 76. Takeda Recent Development Table 77. Pharming Group NV Company Information Table 78. Pharming Group NV Business Overview Table 79. Pharming Group NV Hereditary Angioedema Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Pharming Group NV Hereditary Angioedema Drug Product Portfolio Table 81. Pharming Group NV Recent Development Table 82. Ionis Pharmaceuticals, Inc. Company Information Table 83. Ionis Pharmaceuticals, Inc. Business Overview Table 84. Ionis Pharmaceuticals, Inc. Hereditary Angioedema Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. Ionis Pharmaceuticals, Inc. Hereditary Angioedema Drug Product Portfolio Table 86. Ionis Pharmaceuticals, Inc. Recent Development Table 87. IBio Inc. Company Information Table 88. IBio Inc. Business Overview Table 89. IBio Inc. Hereditary Angioedema Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. IBio Inc. Hereditary Angioedema Drug Product Portfolio Table 91. IBio Inc. Recent Development Table 92. CSL Limited Company Information Table 93. CSL Limited Business Overview Table 94. CSL Limited Hereditary Angioedema Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. CSL Limited Hereditary Angioedema Drug Product Portfolio Table 96. CSL Limited Recent Development Table 97. BioCryst Pharmaceuticals, Inc. Company Information Table 98. BioCryst Pharmaceuticals, Inc. Business Overview Table 99. BioCryst Pharmaceuticals, Inc. Hereditary Angioedema Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. BioCryst Pharmaceuticals, Inc. Hereditary Angioedema Drug Product Portfolio Table 101. BioCryst Pharmaceuticals, Inc. Recent Development Table 102. North America Hereditary Angioedema Drug Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 103. North America Hereditary Angioedema Drug Sales by Country (2021-2026) & (W Units) Table 104. North America Hereditary Angioedema Drug Sales Market Share by Country (2021-2026) Table 105. North America Hereditary Angioedema Drug Sales Forecast by Country (2027-2032) & (W Units) Table 106. North America Hereditary Angioedema Drug Sales Market Share Forecast by Country (2027-2032) Table 107. North America Hereditary Angioedema Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 108. North America Hereditary Angioedema Drug Market Size by Country (2021-2026) & (US$ Million) Table 109. North America Hereditary Angioedema Drug Market Share by Country (2021-2026) Table 110. North America Hereditary Angioedema Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 111. North America Hereditary Angioedema Drug Market Share Forecast by Country (2027-2032) Table 112. Europe Hereditary Angioedema Drug Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 113. Europe Hereditary Angioedema Drug Sales by Country (2021-2026) & (W Units) Table 114. Europe Hereditary Angioedema Drug Sales Market Share by Country (2021-2026) Table 115. Europe Hereditary Angioedema Drug Sales Forecast by Country (2027-2032) & (W Units) Table 116. Europe Hereditary Angioedema Drug Sales Market Share Forecast by Country (2027-2032) Table 117. Europe Hereditary Angioedema Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 118. Europe Hereditary Angioedema Drug Market Size by Country (2021-2026) & (US$ Million) Table 119. Europe Hereditary Angioedema Drug Market Share by Country (2021-2026) Table 120. Europe Hereditary Angioedema Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 121. Europe Hereditary Angioedema Drug Market Share Forecast by Country (2027-2032) Table 122. Asia-Pacific Hereditary Angioedema Drug Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 123. Asia-Pacific Hereditary Angioedema Drug Sales by Country (2021-2026) & (W Units) Table 124. Asia-Pacific Hereditary Angioedema Drug Sales Market Share by Country (2021-2026) Table 125. Asia-Pacific Hereditary Angioedema Drug Sales Forecast by Country (2027-2032) & (W Units) Table 126. Asia-Pacific Hereditary Angioedema Drug Sales Market Share Forecast by Country (2027-2032) Table 127. Asia-Pacific Hereditary Angioedema Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 128. Asia-Pacific Hereditary Angioedema Drug Market Size by Country (2021-2026) & (US$ Million) Table 129. Asia-Pacific Hereditary Angioedema Drug Market Share by Country (2021-2026) Table 130. Asia-Pacific Hereditary Angioedema Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 131. Asia-Pacific Hereditary Angioedema Drug Market Share Forecast by Country (2027-2032) Table 132. Latin America Hereditary Angioedema Drug Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 133. Latin America Hereditary Angioedema Drug Sales by Country (2021-2026) & (W Units) Table 134. Latin America Hereditary Angioedema Drug Sales Market Share by Country (2021-2026) Table 135. Latin America Hereditary Angioedema Drug Sales Forecast by Country (2027-2032) & (W Units) Table 136. Latin America Hereditary Angioedema Drug Sales Market Share Forecast by Country (2027-2032) Table 137. Latin America Hereditary Angioedema Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 138. Latin America Hereditary Angioedema Drug Market Size by Country (2021-2026) & (US$ Million) Table 139. Latin America Hereditary Angioedema Drug Market Share by Country (2021-2026) Table 140. Latin America Hereditary Angioedema Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 141. Latin America Hereditary Angioedema Drug Market Share Forecast by Country (2027-2032) Table 142. Middle East and Africa Hereditary Angioedema Drug Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 143. Middle East and Africa Hereditary Angioedema Drug Sales by Country (2021-2026) & (W Units) Table 144. Middle East and Africa Hereditary Angioedema Drug Sales Market Share by Country (2021-2026) Table 145. Middle East and Africa Hereditary Angioedema Drug Sales Forecast by Country (2027-2032) & (W Units) Table 146. Middle East and Africa Hereditary Angioedema Drug Sales Market Share Forecast by Country (2027-2032) Table 147. Middle East and Africa Hereditary Angioedema Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 148. Middle East and Africa Hereditary Angioedema Drug Market Size by Country (2021-2026) & (US$ Million) Table 149. Middle East and Africa Hereditary Angioedema Drug Market Share by Country (2021-2026) Table 150. Middle East and Africa Hereditary Angioedema Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 151. Middle East and Africa Hereditary Angioedema Drug Market Share Forecast by Country (2027-2032) Table 152. Key Raw Materials Table 153. Raw Materials Key Suppliers Table 154. Hereditary Angioedema Drug Distributors List Table 155. Hereditary Angioedema Drug Customers List Table 156. Research Programs/Design for This Report Table 157. Authors List of This Report Table 158. Secondary Sources Table 159. Primary Sources List of Figures Figure 1. Hereditary Angioedema Drug Image Figure 2. Global Hereditary Angioedema Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Hereditary Angioedema Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Hereditary Angioedema Drug Sales (2021-2032) & (W Units) Figure 5. C1 Esterase Inhibitor Image Figure 6. Global C1 Esterase Inhibitor Sales YoY Growth (2021-2032) & (W Units) Figure 7. Kallikrein Inhibitor Image Figure 8. Global Kallikrein Inhibitor Sales YoY Growth (2021-2032) & (W Units) Figure 9. Selective Bradykinin B2 Receptor Antagonist Image Figure 10. Global Selective Bradykinin B2 Receptor Antagonist Sales YoY Growth (2021-2032) & (W Units) Figure 11. Global Hereditary Angioedema Drug Market Size Overview by Type (2021-2032) & (US$ Million) Figure 12. Global Hereditary Angioedema Drug Market Share by Type 2025 VS 2032 Figure 13. North America Hereditary Angioedema Drug Sales Market Share in Volume by Type in 2025 Figure 14. North America Hereditary Angioedema Drug Sales Market Share in Value by Type in 2025 Figure 15. Europe Hereditary Angioedema Drug Sales Market Share in Volume by Type in 2025 Figure 16. Europe Hereditary Angioedema Drug Sales Market Share in Value by Type in 2025 Figure 17. Asia-Pacific Hereditary Angioedema Drug Sales Market Share in Volume by Type in 2025 Figure 18. Asia-Pacific Hereditary Angioedema Drug Sales Market Share in Value by Type in 2025 Figure 19. Latin America Hereditary Angioedema Drug Sales Market Share in Volume by Type in 2025 Figure 20. Latin America Hereditary Angioedema Drug Sales Market Share in Value by Type in 2025 Figure 21. Middle East and Africa Hereditary Angioedema Drug Sales Market Share in Volume by Type in 2025 Figure 22. Middle East and Africa Hereditary Angioedema Drug Sales Market Share in Value by Type in 2025 Figure 23. Global Top 5 and 10 Hereditary Angioedema Drug Players Market Share by Revenue in 2025 Figure 24. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 25. Hospital Pharmacies Image Figure 26. Global Hospital Pharmacies Sales YoY Growth (2021-2032) & (W Units) Figure 27. Online Pharmacies Image Figure 28. Global Online Pharmacies Sales YoY Growth (2021-2032) & (W Units) Figure 29. Retail Pharmacies Image Figure 30. Global Retail Pharmacies Sales YoY Growth (2021-2032) & (W Units) Figure 31. Global Hereditary Angioedema Drug Market Size Overview by Application (2021-2032) & (US$ Million) Figure 32. Global Hereditary Angioedema Drug Market Share by Application 2025 VS 2032 Figure 33. North America Hereditary Angioedema Drug Sales Market Share in Volume by Application in 2025 Figure 34. North America Hereditary Angioedema Drug Sales Market Share in Value by Application in 2025 Figure 35. Europe Hereditary Angioedema Drug Sales Market Share in Volume by Application in 2025 Figure 36. Europe Hereditary Angioedema Drug Sales Market Share in Value by Application in 2025 Figure 37. Asia-Pacific Hereditary Angioedema Drug Sales Market Share in Volume by Application in 2025 Figure 38. Asia-Pacific Hereditary Angioedema Drug Sales Market Share in Value by Application in 2025 Figure 39. Latin America Hereditary Angioedema Drug Sales Market Share in Volume by Application in 2025 Figure 40. Latin America Hereditary Angioedema Drug Sales Market Share in Value by Application in 2025 Figure 41. Middle East and Africa Hereditary Angioedema Drug Sales Market Share in Volume by Application in 2025 Figure 42. Middle East and Africa Hereditary Angioedema Drug Sales Market Share in Value by Application in 2025 Figure 43. North America Hereditary Angioedema Drug Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 44. North America Hereditary Angioedema Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 45. North America Hereditary Angioedema Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 46. North America Hereditary Angioedema Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Hereditary Angioedema Drug Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 48. Europe Hereditary Angioedema Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Hereditary Angioedema Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. Europe Hereditary Angioedema Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific Hereditary Angioedema Drug Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 52. Asia-Pacific Hereditary Angioedema Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific Hereditary Angioedema Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Asia-Pacific Hereditary Angioedema Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Hereditary Angioedema Drug Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 56. Latin America Hereditary Angioedema Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Hereditary Angioedema Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Latin America Hereditary Angioedema Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa Hereditary Angioedema Drug Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 60. Middle East and Africa Hereditary Angioedema Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa Hereditary Angioedema Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Middle East and Africa Hereditary Angioedema Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Hereditary Angioedema Drug Value Chain Figure 64. Key Raw Materials Price Figure 65. Manufacturing Cost Structure Figure 66. Hereditary Angioedema Drug Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • C1 Esterase Inhibitor
  • Kallikrein Inhibitor
  • Selective Bradykinin B2 Receptor Antagonist
Applications
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
Companies covered
  • Takeda
  • Pharming Group NV
  • Ionis Pharmaceuticals, Inc.
  • IBio Inc.
  • CSL Limited
  • BioCryst Pharmaceuticals, Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Hereditary Angioedema Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Hereditary Angioedema Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Hereditary Angioedema Drug Market by Type
  6. 1.3.1 C1 Esterase Inhibitor
  7. 1.3.2 Kallikrein Inhibitor
  8. 1.3.3 Selective Bradykinin B2 Receptor Antagonist
  9. 1.4 Global Hereditary Angioedema Drug Market Size by Type
  10. 1.4.1 Global Hereditary Angioedema Drug Market Size Overview by Type (2021-2032)
  11. 1.4.2 Global Hereditary Angioedema Drug Historic Market Size Review by Type (2021-2026)
  12. 1.4.3 Global Hereditary Angioedema Drug Forecasted Market Size by Type (2027-2032)
  13. 1.5 Key Regions Market Size by Type
  14. 1.5.1 North America Hereditary Angioedema Drug Sales Breakdown by Type (2021-2026)
  15. 1.5.2 Europe Hereditary Angioedema Drug Sales Breakdown by Type (2021-2026)
  16. 1.5.3 Asia-Pacific Hereditary Angioedema Drug Sales Breakdown by Type (2021-2026)
  17. 1.5.4 South America Hereditary Angioedema Drug Sales Breakdown by Type (2021-2026)
  18. 1.5.5 Middle East and Africa Hereditary Angioedema Drug Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Hereditary Angioedema Drug Industry Trends
  2. 2.2 Hereditary Angioedema Drug Industry Drivers
  3. 2.3 Hereditary Angioedema Drug Industry Opportunities and Challenges
  4. 2.4 Hereditary Angioedema Drug Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Hereditary Angioedema Drug Revenue (2021-2026)
  2. 3.2 Global Top Players by Hereditary Angioedema Drug Sales (2021-2026)
  3. 3.3 Global Top Players by Hereditary Angioedema Drug Price (2021-2026)
  4. 3.4 Global Hereditary Angioedema Drug Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Hereditary Angioedema Drug Major Company Production Sites & Headquarters
  6. 3.6 Global Hereditary Angioedema Drug Company, Product Type & Application
  7. 3.7 Global Hereditary Angioedema Drug Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Hereditary Angioedema Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Hereditary Angioedema Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Hereditary Angioedema Drug Tier 1, Tier 2, and Tier 3
4 Hereditary Angioedema Drug Regional Status and Outlook
  1. 4.1 Global Hereditary Angioedema Drug Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Hereditary Angioedema Drug Historic Market Size by Region
  3. 4.2.1 Global Hereditary Angioedema Drug Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Hereditary Angioedema Drug Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Hereditary Angioedema Drug Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Hereditary Angioedema Drug Forecasted Market Size by Region
  7. 4.3.1 Global Hereditary Angioedema Drug Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Hereditary Angioedema Drug Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Hereditary Angioedema Drug Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Hereditary Angioedema Drug by Application
  1. 5.1 Hereditary Angioedema Drug Market by Application
  2. 5.1.1 Hospital Pharmacies
  3. 5.1.2 Online Pharmacies
  4. 5.1.3 Retail Pharmacies
  5. 5.2 Global Hereditary Angioedema Drug Market Size by Application
  6. 5.2.1 Global Hereditary Angioedema Drug Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Hereditary Angioedema Drug Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Hereditary Angioedema Drug Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Hereditary Angioedema Drug Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Hereditary Angioedema Drug Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Hereditary Angioedema Drug Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Hereditary Angioedema Drug Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Hereditary Angioedema Drug Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Takeda
  2. 6.1.1 Takeda Company Information
  3. 6.1.2 Takeda Business Overview
  4. 6.1.3 Takeda Hereditary Angioedema Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Takeda Hereditary Angioedema Drug Product Portfolio
  6. 6.1.5 Takeda Recent Developments
  7. 6.2 Pharming Group NV
  8. 6.2.1 Pharming Group NV Company Information
  9. 6.2.2 Pharming Group NV Business Overview
  10. 6.2.3 Pharming Group NV Hereditary Angioedema Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Pharming Group NV Hereditary Angioedema Drug Product Portfolio
  12. 6.2.5 Pharming Group NV Recent Developments
  13. 6.3 Ionis Pharmaceuticals, Inc.
  14. 6.3.1 Ionis Pharmaceuticals, Inc. Company Information
  15. 6.3.2 Ionis Pharmaceuticals, Inc. Business Overview
  16. 6.3.3 Ionis Pharmaceuticals, Inc. Hereditary Angioedema Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Ionis Pharmaceuticals, Inc. Hereditary Angioedema Drug Product Portfolio
  18. 6.3.5 Ionis Pharmaceuticals, Inc. Recent Developments
  19. 6.4 IBio Inc.
  20. 6.4.1 IBio Inc. Company Information
  21. 6.4.2 IBio Inc. Business Overview
  22. 6.4.3 IBio Inc. Hereditary Angioedema Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 IBio Inc. Hereditary Angioedema Drug Product Portfolio
  24. 6.4.5 IBio Inc. Recent Developments
  25. 6.5 CSL Limited
  26. 6.5.1 CSL Limited Company Information
  27. 6.5.2 CSL Limited Business Overview
  28. 6.5.3 CSL Limited Hereditary Angioedema Drug Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 CSL Limited Hereditary Angioedema Drug Product Portfolio
  30. 6.5.5 CSL Limited Recent Developments
  31. 6.6 BioCryst Pharmaceuticals, Inc.
  32. 6.6.1 BioCryst Pharmaceuticals, Inc. Company Information
  33. 6.6.2 BioCryst Pharmaceuticals, Inc. Business Overview
  34. 6.6.3 BioCryst Pharmaceuticals, Inc. Hereditary Angioedema Drug Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 BioCryst Pharmaceuticals, Inc. Hereditary Angioedema Drug Product Portfolio
  36. 6.6.5 BioCryst Pharmaceuticals, Inc. Recent Developments
7 North America by Country
  1. 7.1 North America Hereditary Angioedema Drug Sales by Country
  2. 7.1.1 North America Hereditary Angioedema Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Hereditary Angioedema Drug Sales by Country (2021-2026)
  4. 7.1.3 North America Hereditary Angioedema Drug Sales Forecast by Country (2027-2032)
  5. 7.2 North America Hereditary Angioedema Drug Market Size by Country
  6. 7.2.1 North America Hereditary Angioedema Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Hereditary Angioedema Drug Market Size by Country (2021-2026)
  8. 7.2.3 North America Hereditary Angioedema Drug Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Hereditary Angioedema Drug Sales by Country
  2. 8.1.1 Europe Hereditary Angioedema Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Hereditary Angioedema Drug Sales by Country (2021-2026)
  4. 8.1.3 Europe Hereditary Angioedema Drug Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Hereditary Angioedema Drug Market Size by Country
  6. 8.2.1 Europe Hereditary Angioedema Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Hereditary Angioedema Drug Market Size by Country (2021-2026)
  8. 8.2.3 Europe Hereditary Angioedema Drug Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Hereditary Angioedema Drug Sales by Country
  2. 9.1.1 Asia-Pacific Hereditary Angioedema Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Hereditary Angioedema Drug Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Hereditary Angioedema Drug Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Hereditary Angioedema Drug Market Size by Country
  6. 9.2.1 Asia-Pacific Hereditary Angioedema Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Hereditary Angioedema Drug Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Hereditary Angioedema Drug Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Hereditary Angioedema Drug Sales by Country
  2. 10.1.1 South America Hereditary Angioedema Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Hereditary Angioedema Drug Sales by Country (2021-2026)
  4. 10.1.3 South America Hereditary Angioedema Drug Sales Forecast by Country (2027-2032)
  5. 10.2 South America Hereditary Angioedema Drug Market Size by Country
  6. 10.2.1 South America Hereditary Angioedema Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Hereditary Angioedema Drug Market Size by Country (2021-2026)
  8. 10.2.3 South America Hereditary Angioedema Drug Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Hereditary Angioedema Drug Sales by Country
  2. 11.1.1 Middle East and Africa Hereditary Angioedema Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Hereditary Angioedema Drug Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Hereditary Angioedema Drug Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Hereditary Angioedema Drug Market Size by Country
  6. 11.2.1 Middle East and Africa Hereditary Angioedema Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Hereditary Angioedema Drug Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Hereditary Angioedema Drug Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Hereditary Angioedema Drug Value Chain Analysis
  2. 12.1.1 Hereditary Angioedema Drug Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Hereditary Angioedema Drug Production Mode & Process
  7. 12.2 Hereditary Angioedema Drug Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Hereditary Angioedema Drug Distributors
  10. 12.2.3 Hereditary Angioedema Drug Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst